Stockwinners Market Radar for December 28, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EST Cathie Wood's ARK Investment bought 18K shares of Tesla today

19:08 EST Four Corners Property Trust acquires two properties for $6.9M - Four Corners Property Trust "announces the acquisition of a Red Lobster property and a Smokey Bones property for $6.9 million. The properties are located in a highly trafficked corridor in New York and are corporate-operated under triple net leases with a weighted average of 2.5 years of term remaining. The transaction was priced at a 6.5% cap rate, exclusive of transaction costs."

17:54 EST Osisko Gold updates on CSA mine in NSW, Australia - Osisko Gold Royalties (OR) "announces that its wholly-owned subsidiary, Osisko Bermuda Limited has entered into a revised binding agreement with Metals Acquisition Corp. (MTAL) with respect to the purchase of a 100% silver stream on the producing CSA mine in New South Wales, Australia to partially fund MAC's acquisition of the Mine. MAC has filed a preliminary Form F-4 with the U.S. Securities and Exchange Commission for their review purposes, which includes, among other things, details of its proposed acquisition of 100% of the shares of the owner of CSA from a subsidiary of Glencore plc. Separately, OBL and MAC have entered into a backstop financing agreement with respect to an up to US$75 million copper stream. The Backstop Copper Stream may be utilized, in whole or in part, by MAC to fund any shortfall in the equity financing required to complete the Acquisition Transaction, subject to certain conditions precedent."

17:34 EST RXO Inc up 4% at $16.90 after entering S&P SmallCap 600 index

17:29 EST RXO to replace The Joint in the S&P SmallCap 600 at open on January 5

17:26 EST GE HealthCare to replace Vornado Realty Trust in the S&P500 at open on January 4

17:08 EST Mosaic reports October/November potash revenue $780M vs. $529M y/y - Reports October/November Phosphates revenue $785M vs. $902M y/y

17:05 EST Resolute, Paper Excellence merger gets Canadian Competition Bureau approval - The Paper Excellence Group through its wholly-owned subsidiary Domtar a global diversified manufacturer of pulp and specialty, printing, writing, and packaging papers, and Resolute Forest Products, a global forest products company, jointly announced that the Canadian Commissioner of Competition has entered into a consent agreement regarding the parties' business combination. Once the combination has been finalized, Domtar will acquire all of the outstanding common shares of Resolute stock for $20.50 per share and one contingent value right tied to potential duty deposit refunds of up to $500M. The consent agreement filed by the Canadian Commissioner of Competition with the Competition Tribunal today completes one of the remaining conditions to the closing of the transaction. The transaction remains on course to close in the first half of 2023, subject to the satisfaction or waiver of the other conditions to the closing of the merger.

16:39 EST Direct Selling SPAC extends deadline to complete business combination - Direct Selling Acquisition announced that its sponsor, DSAC Partners , has deposited an additional $2,300,000, representing 10c per public share into the Company's trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from December 28 to March 28. The Extension provides the Company with additional time to complete its initial business combination. The Sponsor loaned the Extension Payment to the Company, which loan is convertible, at the Sponsor's discretion, into warrants identical to the warrants issued in the Company's private placement that was consummated in connection with the Company's initial public offering.

16:33 EST Cellectis enters into EUR 40M credit facility with EIB - Cellectis "announced that it has entered into a EUR 40 million credit facility agreement with the European Investment Bank, or EIB. The company plans to use the facility toward the development of its pipeline in the field of allogeneic CAR T-cell product candidates, UCART22, UCART20x22, UCART123 and UCARTCS1."

16:29 EST Lockheed Martin, Boeing protest Army's decision to give Textron FLRAA contract - Sikorsky, a Lockheed Martin (LMT) company, filed a formal protest asking the U.S. Government Accountability Office, GAO, to review the U.S. Army's decision on the Future Long-Range Assault Aircraft, FLRAA, contract. Boeing (BA) supports the protest filed by its Team DEFIANT partner, asking the GAO to review the Army's decision. Based on a thorough review of the information and feedback provided by the Army, Lockheed Martin Sikorsky, on behalf of Team DEFIANT, is challenging the FLRAA decision, saying "The data and discussions lead us to believe the proposals were not consistently evaluated to deliver the best value in the interest of the Army, our soldiers and American taxpayers." Note that earlier this month, the U.S. Army's selected Bell Textron (TXT) for the contract. Reference Link

16:21 EST Cenntro Electric discloses Nasdaq listing notice - Cenntro Electric "announced that on December 22, 2022, it received a notification from The Nasdaq Stock Market LLC that the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company's ordinary shares was below $1.00 per Share for 30 consecutive business days preceding the date of the Notification."

16:18 EST New Mountain Finance extends stock buyback through 2023 - New Mountain Finance "announced that on December 22, 2022 its board of directors authorized an extension of a previously established stock repurchase program. Pursuant to the Repurchase Program, the Company can repurchase up to $50 million worth of its common stock at the discretion of NMFC's management team. The Repurchase Program was set to expire on December 31, 2022, but the Company's board of directors elected to extend the Repurchase Program through December 31, 2023. Unless further extended by NMFC's board of directors, the Company expects the Repurchase Program to be in place until the earlier of December 31, 2023 or until $50M worth of NMFC's outstanding shares of common stock have been repurchased. To date, approximately $2.9M worth of repurchases have been made by the Company under the Repurchase Program."

16:12 EST Cal-Maine Foods says HPAI outlook to continue exert pressure on egg supply - The company states: "Cal-Maine Foods is closely monitoring the current outbreak of HPAI that was first detected in commercial flocks in the U.S. in February 2022. Outbreaks in commercial flocks in the U.S. have most recently occurred during each month from September to December 2022. The current HPAI epidemic has surpassed the prior 2014-2015 outbreak in terms of the number of affected hens in the U.S., and HPAI continues to circulate throughout the wild bird population in the U.S. and abroad. According to the U.S. Centers for Disease Control and Prevention, these detections do not present an immediate public health concern. There have been no positive tests for HPAI at any Cal-Maine Foods' owned or contracted production facility as of December 28, 2022. The USDA division of Animal and Plant Health Inspection Service reported on December 27, 2022, that approximately 43.3 million commercial layer hens and 1.0 million pullets have been depopulated due to HPAI this year. The Company believes the HPAI outbreak will continue to exert downward pressure on the overall supply of eggs, and the duration of these effects will depend in part on the timing of replenishment of the U.S. layer hen flock. Prior to the outbreak of HPAI in February 2022, the layer hen flock five-year average from 2017 through 2021 was comprised of approximately 328 million hens. According to a LEAP Market Analytics report dated December 8, 2022, the layer hen inventory is not projected to exceed the 328 million mark again until December of 2023. Layer hen numbers reported by the USDA as of December 1, 2022, were 308 million, which represents a decrease of 5.8% compared with the layer hen inventory a year ago. However, the USDA also reported that the hatch from July 2022 through November 2022 increased 5.8% as compared with the prior-year period. Cal-Maine Foods believes it has been mindful and proactive in implementing and maintaining robust biosecurity programs across all its locations and facilities."

16:09 EST Paychex VP Gioja sells $1.6M in company shares - Paychex VP Michael Gioja disclosed in a regulatory filing that he had sold 13,744 shares of company stock at $115.30 per share on December 28, for a total transaction amount of $1,584,683.

15:39 EST SINTX Technologies Inc trading resumes

15:05 EST Medirom Healthcare Technologies Inc-ADR trading resumes

14:41 EST Lanvin Group Holdings Ltd trading resumes

14:32 EST Disney says 'Avatar: The Way of Water' tops $1B in global sales - Disney announced that 20th Century Studios and Lightstorm Entertainment's "Avatar: The Way of Water" has surpassed $1B globally after just 14 days. "Avatar: The Way of Water" has passed "Jurassic World: Dominion" to become the number two release of 2022 and the number three release of the pandemic era, Disney pointed out. Reference Link

14:20 EST TG Therapeutics trading resumes

13:57 EST TG Therapeutics to resume trading at 2:20 p.m. ET - Shares of TG Therapeutics are set to resume trading at 2:20 p.m. ET, with quotation scheduled to resume at 2:15 p.m. ET, according to Nasdaq.

13:52 EST TG Therapeutics announces FDA approval of Briumvi - TG Therapeutics announced the U.S. Food and Drug Administration has approved Briumvi for the treatment of relapsing forms of multiple sclerosis, or RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Briumvi is "the first and only anti-CD20 monoclonal antibody approved for patients with RMS that can be administered in a one-hour infusion following the starting dose," the company stated. Michael Weiss, the company's Chairman and CEO, stated, "Today's FDA approval marks an exciting day for everyone touched by MS and everyone that has worked on the development of Briumvi. We believe in the importance of treatment alternatives for patients and believe the profile of Briumvi offers unique attributes to patients and physicians alike. We have built a strong commercial team with deep knowledge of the MS landscape and look forward to launching in Q1 2023. We want to thank the patients and their families, the clinical investigators and their teams, and our advisors for their support and participation in our trials, and for helping us get to this point. We remain committed to the patients we serve and providing seamless access to Briumvi once launched."

13:45 EST BioAffinity considering EU, China after U.S., CEO says - BioAffinity Technologies (BIAF) focuses on the development of noninvasive, early-stage cancer diagnosis, and targeted cancer treatment. In an exclusive interview with The Fly, the company's President and CEO Maria Zannes talked about BioAffinity's CyPath Lung test: "We will be looking at the U.S. first, but we have strong patent portfolio so we'll also be considering the EU and China and the rest of Asia. Lung cancer has an estimated 16 to 18 million people at high risk just in the U.S. alone. When lung cancer is caught is unfortunately usually caught at a late stage. We didn't have screening for lung cancer. But now we do. It's extremely important for people at high risk to get screened for lung cancer at a low dose CT. The issue, however, with that screening is that it has a low positive predictive value, which means that for those individuals who get a positive result, out of the 100 only 4 have the disease. This causes an uncertainty and unease. There is where CyPath Lung comes in. It's a test that is used after a physician and their patient receive a suspicious finding and used afterwards to determine what's next. Because what's next now are invasive procedures. Our text can step in and can offer a patient a very simple test, a very easy test to clarify what should be next: if they should wait or if a more aggressive follow-up is needed. We really see CyPath shifting, moving the paradigm on how screening can be done, and how people with high risk can be diagnosed and do it so at an early stage. We have completed a test validation trial, a clinical trial where we had very high sensitivity and specificity." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company.

13:23 EST BioAffinity CEO says 'very successful IPO' thanks to compelling story - BioAffinity Technologies (BIAF) focuses on the development of noninvasive, early-stage cancer diagnosis, and targeted cancer treatment. In an exclusive interview with The Fly, the company's President and CEO Maria Zannes talked about going public back in September: "The IPO itself required a tremendous effort. We had a very experienced team of professionals that were very dedicated to get us to that public status. I don't have to tell people how difficult this market was but we had a very compelling story -- and we continue to have it, and we had a very successful IPO. We have a very accurate test, very patient friendly non-invasive test for the early detection of lung cancer, which is a leading cancer killer and a very difficult cancer because it's usually caught in such late stages. The funding and the going public was very important to us because the funds are the foundation to advance our strategic goals in commercializing CyPath Lung. Our test is commercial, it's a laboratory developed test that is offered by our partner - Precision Pathology Services -- in San Antonio, Texas. The first step is very limited marketing to launch to insure we have the right branding, the right messaging, the most efficient methods in media that resonate with the family practitioners and pulmonologists that will order the test. The funds and going public also provide for development of diagnostics of other lung diseases. We are looking forward to having more eyes on us and to tell our story because we think we have a really good one." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.

13:07 EST Ault Global Holdings trading halted, news pending

13:00 EST Netherlands market expected to be next after U.S., BioAffinity CEO says

13:00 EST BioAffinity CEO says 'back to normal' after early COVID-related delays

12:58 EST TG Therapeutics up 9% to $8.51 after FDA approves Briumvi for relapsing MS

12:50 EST TG Therapeutics trading halted, volatility trading pause

12:16 EST ImmunoGen rallies 7% after William Blair highlights new NCCN guidelines

12:00 EST Huya falls -16.7% - Huya is down -16.7%, or -72c to $3.62.

12:00 EST Cooper-Standard rises 8.5% - Cooper-Standard is up 8.5%, or 58c to $7.39.

12:00 EST Vertical Aerospace rises 16.3% - Vertical Aerospace is up 16.3%, or 58c to $4.14.

10:00 EST United States Natural Gas Fund falls -9.2% - United States Natural Gas Fund is down -9.2%, or -$1.49 to $14.63.

10:00 EST Community Bancshares falls -24.2% - Community Bancshares is down -24.2%, or -$7.15 to $22.42.

10:00 EST Atento rises 9.7% - Atento is up 9.7%, or 40c to $4.53.

09:54 EST Model Performance Acquisition Corp trading resumes

09:47 EST GreenTree Hospitality falls -5.9% - GreenTree Hospitality is down -5.9%, or -23c to $3.69.

09:47 EST Community Bancshares falls -24.0% - Community Bancshares is down -24.0%, or -$7.10 to $22.47.

09:47 EST Atento rises 9.7% - Atento is up 9.7%, or 40c to $4.53.

09:44 EST Model Performance Acquisition Corp trading halted, volatility trading pause

09:31 EST Lightjump Acquisition Corp trading halted, volatility trading pause

09:23 EST SJW Group appoints Bruce Hauk as chief operating officer - SJW Group announced that its board of directors has appointed Bruce Hauk as chief operating officer, effective January 1, 2023. Hauk will lead regulated water and wastewater utility operations across SJW Group's geographically diverse footprint. The company's local operations now serve more than 1.5M people in California, Connecticut, Maine and Texas. Hauk joined SJW Group in August as its chief corporate development and strategy officer. Prior to joining SJW Group, Hauk was president of NextEra Water.

09:05 EST CareCloud selected by Alpine Ear Nose and Throat PC - CareCloud announced Alpine Ear Nose and Throat PC has selected CareCloud's Meridian division's revenue cycle management solution to support its administrative operations and improve cashflow for the Colorado-based practice. With three locations serving Northern Colorado, Alpine offers general ear, nose and throat, ENT, services, audiology, allergy and vestibular therapy, as well as facial plastics. Alpine selected Meridian through trusted referrals that endorsed Meridian's medical billing experience and prior success in streamlining processes, eliminating coding errors, and improving service-level agreements.

09:04 EST Workhorse Group says SEC concludes investigation without enforcement action - The Company received notice from the Securities and Exchange Commission that the previously disclosed investigation of the Company has concluded, and the SEC does not intend to recommend any enforcement action against the Company at this time.

09:03 EST Dominari Holdings purchased 4,000 of its shares at $3.10 per share - Dominari Holdings provided an update on the $2M share repurchase program authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part of our recently approved buyback program."

09:01 EST iClick Interactive Asia announces $5M share repurchase program - iClick Interactive Asia Group announced its board of directors has approved a share repurchase program in which the Company may purchase its own ADSs with an aggregate value of up to US$5M from January 1, 2023 to December 31, 2023. iClick expects to fund the repurchase from its existing cash balance, including cash generated from its operations.

08:57 EST Clubhouse Media closes another brand deal with social media star Sommer Ray - Clubhouse Media Group announced that they have finalized another brand promotional deal with fitness model and iconic social media star, Sommer Ray. The deal was consummated through CMGR's majority held entity, The Reiman Agency. "It is always a pleasure to work with Sommer and her team" said Alden Reiman, President of The Reiman Agency. "She has built a tremendously engaged audience that aligns directly with the consumer demographics of many brands. I look forward to building on this relationship in the future."

08:53 EST MicroStrategy raised bitcoin holdings by 2,500 bitcoins from Oct. 31 to Dec. 27 - In a regulatory filing, MicroStrategy announced that during the period between November 1 and December 21, MicroStrategy, through its wholly-owned subsidiary MacroStrategy LLC, acquired approximately 2,395 bitcoins for approximately $42.8M in cash, at an average price of approximately $17,871 per bitcoin, inclusive of fees and expenses; On December 22, MacroStrategy sold approximately 704 bitcoins for cash proceeds of approximately $11.8M, at an average price of approximately $16,776 per bitcoin, net of fees and expenses. MicroStrategy plans to carry back the capital losses resulting from this transaction against previous capital gains, to the extent such carrybacks are available under the federal income tax laws currently in effect, which may generate a tax benefit; on December 24, MacroStrategy acquired approximately 810 bitcoins for approximately $13.6M in cash, at an average price of approximately $16,845 per bitcoin, inclusive of fees and expenses. After giving effect to the transactions described above, MicroStrategy, together with its subsidiaries, increased its bitcoin holdings by 2,500 bitcoins, from approximately 130,000 bitcoins as of October 31, 2022, to approximately 132,500 bitcoins as of December 27. The approximately 132,500 bitcoins held by MicroStrategy and its subsidiaries as of December 27, 2022 were acquired at an aggregate purchase price of approximately $4.03B and an average purchase price of approximately $30,397 per bitcoin, inclusive of fees and expenses. As previously disclosed, on September 9, MicroStrategy entered into a sales agreement with Cowen and Company and BTIG as sales agents, pursuant to which MicroStrategy may issue and sell shares of its class A common stock, having an aggregate offering price of up to $500M from time to time through the agents. On December 28, the company also announced that, during the period between October 1 and December 27, MicroStrategy had issued and sold an aggregate of 218,575 shares under the sales agreement, at an average gross price per share of approximately $213.16, for aggregate net proceeds to MicroStrategy, less sales commissions and expenses, of approximately $46.4M.

08:51 EST PetVivo announces application for dual listing on Upstream - PetVivo Holdings announced that it has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex and MERJ Exchange Limited.

08:38 EST Luckin Coffee appoints Joel Getz to board of directors - Luckin Coffee announced the appointment of Joel Getz as an independent director of its Board of Directors. With the appointment of Mr. Getz, the Board is expanded to ten directors. Getz currently serves as the Deputy Dean for Alumni, Development, and Special Initiatives at the Yale School of Management, which he joined in February 2008.

08:37 EST GreenPower names Tritt as VP of Medium Duty, Commercial Vehicles SalesCanoo - GreenPower Motor (GP) announced that Claus Tritt has joined the company as Vice President, VP, of Medium Duty and Commercial Vehicle Sales. Most recently Tritt served in a sales and business development role at Canoo (GOEV).

08:34 EST Biostage selects Iqvia to manage FDA-approved clinical trial - Biostage (BSTG) announced that it had selected IQVIA (IQV) as the contract research organization to manage its first clinical trial. The FDA-approved clinical trial is an open-label trial assessing both safety and efficacy in up to ten patients requiring the removal of up to 6cm of their esophagus for any reason at up to five hospitals in the U.S. The primary endpoint is the establishment of a continuous biological conduit at three months following implantation. David Green, Biostage's founder, Chair of the Board and interim Chief Executive Officer commented, "We are very pleased to be partnering with IQVIA to perform the clinical trials needed to bring our Biostage Esophageal Implant product candidate to the patients who need it. According to the American Cancer Society, current treatment options for patients diagnosed with esophageal cancer result in only 20% survival at five years and according to the World Health Organization's International Agency for Research on Cancer, every year more than 600,000 patients worldwide are diagnosed with esophageal cancer."

08:32 EST Unicycive meets primary endpoint in BE study comparing Renazorb to Fosrenol - Unicycive Therapeutics announced that the primary endpoint was met in the Company's pivotal bioequivalence, or BE, study comparing Renazorb to Fosrenol. Based on the topline results, pharmacodynamic, or PD, BE of Renazorb to Fosrenol was established and met the regulatory criteria for PD BE in the healthy volunteer BE study. Renazorb is an investigational phosphate binding agent utilizing proprietary nanoparticle technology that is being developed to treat hyperphosphatemia in chronic kidney disease, or CKD, patients on dialysis. If approved, Renazorb may dramatically reduce the pill burden that patients endure with currently available medications. The global market opportunity for treating hyperphosphatemia is projected to be in excess of $2.5B in 2022, with the U.S. Positive results are from a randomized, open-label, two-way crossover BE study to establish PD BE between Renazorb and Fosrenol. The study enrolled 40 subjects per treatment arm. The study design, including the dose, primary endpoint, and sample size, was reviewed, and aligned by the FDA before the initiation of the study.

08:29 EST Akebia reports termination of agreement between Keryx and BioVectra - In a regulatory filing, Akebia Therapeutics disclosed that on December 22, the company, Keryx Biopharmaceuticals, a wholly-owned subsidiary of the company, and BioVectra entered into a termination and settlement agreement. Pursuant to the termination agreement, Keryx and BioVectra agreed, among other things, to terminate, effective immediately, any and all existing agreements entered into between the parties in connection with the manufacture and supply, by BioVectra to the company, of ferric citrate drug substance for the company's proprietary product, Auryxia. "Under the terms of the termination agreement, the company has agreed to pay to BioVectra a total of $32,500,000, consisting of (i) an upfront payment of $17,500,000 and (ii) six quarterly payments of $2,500,000 starting in April 2024, in consideration for the termination of the BioVectra agreements and all obligations thereunder, and the covenants and agreements set forth in the termination agreement, including the settlement and release of all disputes and claims and the return of certain materials and documents as provided therein. In addition, each of the company and BioVectra have released one another from all existing and future claims and liabilities arising from the BioVectra agreements, subject to certain customary exceptions," the filing stated.

08:20 EST Meta Materials to showcase global technology collaborations at CES 2023 - Meta Materials announced that the Company will be demonstrating a range of technologies at CES 2023 which highlight global collaborations in the areas of 5G Communications, Augmented Reality Eyewear, and Li-ion Battery Components. META and Sekisui Chemical are working together to improve the performance and coverage of 5G and future 6G networks. META works closely with Covestro which supplies key photosensitive raw materials used in holographic applications and augmented reality eyewear. META and PPG are collaborating to develop dynamic dimming functionality of META's NANOWEB transparent conductive film combined with PPG electrochromic gels and META's ARfusion platform. META has partnered with DuPont Teijin Films and Mitsubishi Electric Europe to scale up a proprietary, high volume, roll-to-roll manufacturing system for film-based, metal/polymer copper current collectors.

08:17 EST Polarean Imaging announces FDA approval of XENOVIEW - Polarean Imaging announces that the U.S. Food and Drug Administration has granted approval for its drug device combination product, XENOVIEW. XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. XENOVIEW has not been evaluated for use with lung perfusion imaging. Polarean also announces that, simultaneously with the approval of the XENOVIEW NDA, two 510(k) devices were cleared by the FDA that will further support a successful launch of the technology into the clinical marketplace: XENOVIEW VDP is image processing software that analyzes a pulmonary hyperpolarized 129-Xe MR image and a proton chest MR image to provide visualization and evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. This image analysis platform quantifies normalized xenon intensity of a ventilated space using a pulmonary hyperpolarized 129-Xe ventilation MR image and accompanying proton chest MR image. The software will be used by clinicians to assist in the interpretation and numerical classification of hyperpolarized 129-Xe ventilation MR images. The Polarean XENOVIEW 3.0T Chest Coil is a flexible, single channel, transmit-receive RF coil tuned to 129Xe frequency on a 3.0T MRI magnetic field of a compatible MRI scanner. The Polarean XENOVIEW 3.0T Chest Coil is indicated to be used in conjunction with compatible 3.0T MRI scanners and approved xenon Xe 129 hyperpolarized for oral inhalation for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older. The Chest Coil is intended to be worn by a patient who inhales hyperpolarized 129Xe gas to obtain an MR image of the regional distribution of hyperpolarized 129Xe in the lungs.

08:16 EST Elys Game Technology issues letter to shareholders - Elys Game Technology issued a letter to shareholders. Letter, signed by Michele Ciavarella, Executive Chairman, began: "Dear Shareholders, As we approach the conclusion of another year of formative developments for Elys, I would like to take this opportunity to highlight several positive accomplishments and assuage any concern in light of the recent turmoil in both global and U.S. markets and the negative impact it has had on the gaming sector, particularly on our stock price, and to further discuss the sustainability of the Company and dedication of our founders and senior management with the upcoming annual meeting of shareholders." Highlights included information regarding the company's road-map, the transition from expansion to profits; scaling up U.S. retail operations; mobile segment strategy; and shareholder value.

08:12 EST Brookfield Business Partners receives exemptive relief in Ontario - Brookfield Business Partners announced that it has received exemptive relief from the Ontario Securities Commission from the requirements to call a special unitholder meeting and to send an information circular to unitholders in connection with the proposed sale of its nuclear technology services operation, Westinghouse Electric Company. As previously described in our November 4, 2022 press release, our application for exemptive relief was submitted on the basis that holders of more than 50% of the votes eligible to be cast have provided us with written support to vote in favor of the Transaction. The Transaction is expected to close in the second half of 2023, subject to certain conditions, including the receipt of unitholder approval (as described above), regulatory approvals and other customary conditions.

08:10 EST TMG's Society Pass acquires Indonesian agency More Media - Thoughtful Media Group, or TMG, the Thailand-based social commerce-focused, premium digital advertising network of Society Pass Incorporated, announces the acquisition of More Media, a leading Indonesia-based creative design and branding agency. The More Media acquisition extends TMG's social commerce and influencer advertising business reach beyond Thailand and Vietnam and into the booming Indonesia digital advertising sector. Founded in 2021 as an international caliber design and branding agency serving up-and-coming Indonesian companies in the beauty, F&B, e-commerce and logistics sectors, More Media has grown its client base through quick deployment of value-added services and understanding of the local market tastes. "According to Grand View Research, the global influencer marketing platform market size was valued at $10.39B in 2021 and is now expected to expand at a compound annual growth rate of 33.4% from 2022 to 2030. With this explosion in influencer advertising and social commerce throughout SEA, Thoughtful Media Indonesia is well positioned to generate significant revenues in 2023 and occupies a central position in Indonesia's large and fast-paced growing advertising market, both online and offline," explains Eugenia Agnes Gusti, Co Founder, More Media.

08:07 EST Erayak reports 437% generators sales increase in first half of FY22 - Erayak Power Solution Group provided the following information concerning the Company's generator sales in 2022. For the first half of 2022, sales of the Company's generators were $3.65M, a 437% increase compared to $835,000 in the first half of 2021. Generator sales in the second half of 2021 were $720,000 and the generator sales in the second half of 2022 are expected to continue similar growth rate as seen in the first half of 2022. The increase in generator sales is due to the continuous impact of the Russia-Ukraine situation this year, resulting in an unprecedented energy crisis that has significantly increased demand for the Company's generators. 65% of generator sales are ultimately distributed to Europe.

08:06 EST Acasti says preliminary results of GTX-102 study met all outcome measures - Acasti Pharma announces that the preliminary topline results of the pharmacokinetic bridging study for GTX-102 met all outcome measures. The objectives of the study were to evaluate the bioavailability, pharmacokinetics, and safety of GTX-102, a novel, concentrated oral-mucosal metered spray of betamethasone in healthy volunteers. This new formulation is intended to improve the neurological symptoms of Ataxia Telangiectasia in a pediatric population for which there are currently no FDA-approved therapies. GTX-102 can be sprayed conveniently over the tongue of A-T patients, who often have difficulties swallowing. This PK study was the next step in the proposed 505(b)(2) regulatory pathway for GTX-102. This PK bridging study is a Phase 1, randomized, open-label, crossover study in healthy adult subjects to evaluate the comparative bioavailability, PK, and safety of GTX-102 administered as an oral spray compared to intramuscular betamethasone, and to an oral solution of betamethasone, which is available in Europe but not approved in the US. The betamethasone OS was shown to reduce neurological symptoms in children with A-T in a published multicenter, double-blind, randomized, placebo-controlled crossover trial conducted in Italy. The primary objective of this PK bridging study was to evaluate and characterize the PK profile of GTX-102 as an oral spray. A total of 48 healthy adult subjects were enrolled in this single center, 5-treatment, 8-sequence, 2-period cross-over study. The 5 treatments assessed in the study were: GTX-102: low dose at 0.0125 mg/kg, medium dose at 0.05 mg/kg, and high dose at 0.1 mg/kg; OS betamethasone at 0.1 mg/kg; IM betamethasone at 0.1 mg/kg. Each subject received a single dose of 2 treatments in a cross-over fashion, in a randomized sequence over 2 treatment periods separated by 15 days. The dosing started on September 13, 2022 and ended on November 24, 2022. Betamethasone blood levels were compared between all treatment groups. GTX-102 PK study outcome measures definitions and preliminary topline findings are as follows: Primary outcome measures and their definitions include: AUC0-72 is the area under the concentration time curve up to 72 hours post-dose; AUC is the area under the concentration time curve extrapolated to infinity; Cmax is the maximum concentration occurring between 0 hour to 72 hours after study drug administration. GTX-102 given at doses of 0.0125, 0.5 or 0.1 mg/kg, showed betamethasone blood concentrations that were highly predictable and consistent based on AUC and Cmax, indicating good linearity and dose-proportionality. Following the high dose of GTX-102, betamethasone blood concentrations were within the same range of exposure as IM betamethasone, based on AUC. The IM formulation of betamethasone will serve as a bridge for GTX-102 in the context of the proposed 505(b)(2) regulatory pathway. In addition, Betamethasone blood concentrations following the high dose of GTX-102 were within the same range of exposure as OS betamethasone, based on AUC. This OS formulation was the same one that was used by Zannolli et al and may serve as a clinical comparator for further clinical development of GTX-102. There was statistically no significant difference between GTX-102 when comparing a fast rate of administration to a slow rate, as indicated by Cmax and AUC. This is important because being able to use the fast or the slow rate of administration may provide greater flexibility for patients and caregivers. The Cmax of GTX-102 was within the same range of exposure as the OS, but the Cmax for the IM formulation was lower than both GTX-102 and the OS, as well as what has been reported previously for the IM in the literature. It is important to note that achieving bioequivalence with the IM was not an objective of this study, nor was it expected. No serious adverse events were reported during the study. AEs leading to study discontinuation consisted of cough/fever/body pain/stuffy nose, Covid-19 and elevated creatinine kinase, and all events occurred prior to receiving the second treatment. None were judged as being related to the study drugs by the investigator. The most frequent drug-related AE was mild headache. Based on this data, Acasti will work with our clinical experts and FDA to determine the best final dosing regimen for GTX-102 to incorporate into our Phase 3 study design.

08:05 EST Alzamend Neuro teams with UofM on ALZN002 trial for Alzheimer's - Alzamend Neuro announced that it is partnering with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase I/IIA clinical trial of ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. "We are thrilled to add the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami to the team and have full confidence in their ability to assist us with our Phase I/IIA clinical trial of ALZN002," said Stephan Jackman, Chief Executive Officer of Alzamend. "We strongly believe that the ALZN002 patient-specific immunotherapeutic vaccine has the potential of fostering tolerance to treatment for safety purposes while stimulating the immune system to reduce the brain's beta-amyloid protein burden, resulting in reduced Alzheimer's signs and symptoms. We are advancing the process and expect to initiate this study in the first quarter of 2023." "We look forward to reporting topline data from the Phase IIA MAD study in the second quarter of 2023," said Mr. Jackman. "We are one step closer to providing patients, caregivers and clinicians with a major improvement over current lithium-based treatments that can help over 40 million Americans suffering from Alzheimer's, bipolar disorder, MDD and PTSD. We look forward to completing the Phase IIA MAD study and further advancing clinical development of this promising potential therapeutic."

08:03 EST PDS Biotechnology announces interim data in a Phase 2 trial of PDS0101 - PDS Biotechnology announced expanded interim data in a Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus, or HPV, -positive cancers. The triple combination of PDS0101 with the tumor-targeting IL-12 fusion protein M9241, and bintrafusp alfa, a bifunctional fusion protein targeting two independent immunosuppressive pathways, is being studied in CPI-naive and CPI-refractory patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar cancers. The triple combination Phase 2 trial is being conducted at the Center for Cancer Research, or CCR, at the National Cancer Institute, or NCI, one of the Institutes of the National Institutes of Health. All patients in the study had failed prior treatment with chemotherapy and 90% had failed radiation treatment. The interim efficacy data involves 37 HPV16-positive evaluable patients, including 29 patients who have, in addition, failed treatment with CPIs. Highlights of the expanded interim data are as follows and are consistent with the results presented at American Society of Clinical Oncology, or ASCO, Annual Meeting 2022 and prior interim data announced in October: Both M9241 and bintrafusp alfa are owned by Merck KGaA, Darmstadt, Germany, and its affiliates.

08:02 EST Heliogen receives noncompliance notification from Nasdaq - Heliogen announced that on December 23, it received written notice from the New York Stock Exchange that the average closing price of its common stock over the prior consecutive 30 trading-day period was below $1.00 per share, which is the minimum average share price for continued listing on the NYSE.

08:00 EST WeTrade enters cooperations with Fujian Kunyue Medical Supplies - WeTrade Group announced that the Company has entered into strategic cooperation with Fujian Kunyue Medical Supplies Co., under which WeTrade would use multi-dimensional SaaS technology to open online stores for Kunyue Medical on Alipay and other platforms, launch third-party services, and utilize digital management and refined operations to help Kunyue Medical's business innovation and growth. To date, Kunyue Medical has achieved an average daily online sales order volume of over 50,000 units in Alipay's online store, Epidemic Inspection Pass. Hechun Wei, Chief Executive Officer of the Company, commented, "With the development of cloud computing, big data, and other technologies, global leading biopharmaceutical companies continue to build their core competitiveness through digitalization, and the living space for traditional pharmaceutical companies has since been negatively impacted. Therefore, the topic on how to successfully carry out digital transformation has become increasingly important for biopharmaceutical companies. Y-Health has absolute advantages in helping these biomedical companies achieve their desired digital transformation. The cooperation with Kunyue Medical is just the beginning, and we will reach cooperation with more biomedical companies to further improve the layout of the big health industry and realize the diversified development of the Company's business."

07:33 EST AirBoss of America announces $410M contract awarded to Access Bio - AirBoss of America announced that the Defense Logistics Agency, or DLA, has awarded an Indefinite Delivery/Indefinite Quantity, or IDIQ, contract valued at up to $410M to Access Bio, an industry leader in medical testing and diagnostics, supported by a U.S. coalition including AirBoss Defense Group, or ADG, Maddox Defense, and a network of US test kit component suppliers. This competitively awarded contract for the delivery of Made in America COVID test kits supports the US Government's on-going response to the COVID pandemic. The award demonstrates the US Government's strategic shift toward an American-made and sourced policy that is intended to ensure domestic industrial base capability and capacity in areas critical to the US response to any national emergency. Access Bio has already received, and commenced deliveries under, the first order of approximately one half of this IDIQ contract, valued at $205M. ADG expects to generate $19M in revenue during the next six months as this order is completed, and up to an aggregate of $38M over the lifetime of the contract.

07:12 EST Argo Blockchain to sell Helios facility to Galaxy for $65M - Argo Blockchain "announces that it has entered into definitive agreements with Galaxy Digital Holdings, Ltd. under which an Argo subsidiary will sell its Helios facility in Dickens County, Texas for $65M and refinance its asset-backed loans. Additionally, Galaxy has agreed to host Argo's mining machines located at Helios. The transactions are expected to close on Wednesday, 28 December 2022. Under a two-year hosting agreement with Galaxy, Argo's 23,619 Bitmain S19J Pro mining machines currently operating at Helios will remain in operation at Helios. As the owner of Helios, Galaxy intends to enter into a fixed-price power purchase agreement with a licensed retail electricity provider to procure electricity for the facility. The hosting agreement provides that Argo will have access to this electricity at the PPA rate. Argo will pay Galaxy a hosting fee and will collaborate on designing a curtailment strategy in order to participate in certain demand response programs offered by the Electric Reliability Council of Texas, which manages the Texas power grid. The hosting agreement allows Argo to keep its mining machines operating at Helios and mitigate any mining machine downtime from the sale of the Helios facility. Furthermore, the company believes that the immersion-cooling system it developed and implemented at Helios provides for a superior operating environment for these machines, representing approximately 2.36 EH/s."

07:08 EST SPI Energy secures two provisional patents for solar module manufacturing - SPI Energy "announced Solarjuice Technology, the company's solar manufacturing division, has secured two provisional patents relating to a rework apparatus that achieves EVA, back sheet, and whole solar cell string replacement in a solar module production line and another patent relating to a solar cell replacement machine. These two patents will achieve great improvements in the solar module production field. The first patent is for a device relating to the rework process during the manufacture of solar modules. This device can be used for an EVA, back sheet, and whole solar cell string replacement during manufacturing. The second patent will create a mechanism for replacing defective solar cells from a given solar string during the fabrication process of the solar module. This solar cell replacement can take place when a defect is diagnosed in a specific solar string before the actual lamination, or when the local positioning information for the defective solar cell is provided by the previous quality control operation. This process will also yield reduced time for both identification and replacement of any defective solar cells."

07:06 EST DoubleDown announces results of EGM held on December 28 - DoubleDown Interactive announced that at the extraordinary general meeting of shareholders held on December 28, 2022 at 11:00 a.m., or December 27, 2022 at 9:00 p.m., in Seoul, Korea, the shareholders of record as of December 5, 2022, approved the reduction of the Company's capital reserve in the amount of KRW 330B pursuant to Article 461-2 of the Korean Commercial Code, as originally proposed by the Company's board of directors.

07:03 EST Akoustis receives first design win in 5G mobile from Tier-1 RF component company - Akoustis Technologies announced that it has received its first design win in 5G mobile from a leading multi-billion-dollar Tier-1 RF component company customer. The XBAW filter is designed into a new multiplexer product that is expected to ship in the first half of calendar 2023 as part of a major chipset OEM reference design. The filter solution leverages one of Akoustis' new wafer-level-packages, or WLP, developed and manufactured its Canandaigua, New York fab. The new XBAW design is being used to address difficult coexistence issues between 5G mid bands and WiFi 6E 5 to 7 GHz bands. The customer is considering additional applications for XBAW in future modules for 5G smartphones, tablets, wearables, and other mobile devices after the successful completion of this first solution. Akoustis began shipping pre-production chips against customer purchase orders for development, sampling and qualification during the quarter ending December 31. Given the rapidly growing sales funnel activity, as well as ongoing interaction with customers regarding expected ramps in 5G mobile, Wi-Fi 6, and Wi-Fi 6E in calendar 2023, the Company is completing the annual production capacity increase at its New York fab to approximately 0.5 billion filters per year.

07:01 EST Innovative Eyewear announces license agreement with Authentic Brands Group - Innovative Eyewear announced that through an agreement with Authentic Brands Group, it has licensed the iconic outdoor brand Eddie Bauer for smart eyewear. The Eddie Bauer smart eyewear collection is expected to launch in 2023.

06:49 EST Ferguson announces transaction in own shares - Ferguson announces that it purchased a total of 260,000 of its ordinary shares in the period from December 19, 2022 up to and including December 23, 2022 in connection with its $2.5B share repurchase program. The Company intends to hold these shares in treasury. Following the purchase of these shares, the number of shares held by the Company in treasury will be 24,836,019.

06:34 EST New Found Gold reviews 2022 year of exploration at Queensway - New Found Gold reviews the 2022 year of exploration at its 100%-owned Queensway Project. The Company entered 2022 with significant working capital and an aggressive drill plan to continue to build off initial discoveries made along a 2.7km stretch of the Appleton Fault Zone, which included Keats, Lotto, and Golden Joint. The discovery of multiple zones validated management's working model that gold mineralization at Queensway is spatially associated with the AFZ that strikes over 100km+ of the Queensway Project producing a large territory of prospective ground yet to be explored. Building on these early successes, in 2022 New Found: Discovered multiple new zones along the AFZ, including Keats North, the Keats South Extension, Lotto North, and Keats West; Intercepted 42.6 g/t Au over 32m at Keats West, a new discovery that remains open in all directions and, more importantly, proves the west side of the highly prospective AFZ is host to high-grade epizonal style gold mineralization, opening up a vast unexplored domain. Drilled 184,911m in 2022, a record year of core production. Approximately 319,000m of the ongoing 400,000m drill program has been completed to date, with results pending for ~60,000m. Completed an inaugural drill program at Queensway South, drilling 7,254m across 33 holes, with assays pending. Initiated the use of Chrysos PhotonAssay method, through MSALABS in Val-d'Or, providing a more efficient, cost-effective, and environmentally friendly alternative to the traditional fire assay method for gold determination. Significantly expanded its exploration team with 257 workers now on site including 165 contractors and 92 employees. Currently, 90% of New Found's workforce calls Newfoundland home. Appointed Ron Hampton as Chief Development Officer to accelerate the Queensway Project through advanced exploration, environmental permitting, and into the project development phase. Completed construction of the Company's 25,000 ft2 "Giga-Shack" core processing facility, with a grand opening planned for January 2023. Optioned 13,755ha of additional ground at Queensway North, which covers 6.1km of the AFZ and 7.9km of the JBP Fault Zone, where field crews have begun soil sampling programs. Raised $50M in a bought deal financing led by Bank of Montreal at a price of $8.00 per share, resulting in minimal dilution of 3.6%. New Found ends the year with $90.6M in cash and marketable securities.

06:19 EST Franco-Nevada provides update on Cobre Panama mine - Franco-Nevada has been advised by its partner First Quantum Minerals of the following updates in respect of the Cobre Panama mine: Formal discussions with the Government of Panama resumed on December 26. First Quantum's subsidiary, Minera Panama, S.A., or MPSA, the operator of Cobre Panama, is in the process of responding to the Ministry of Commerce and Industries direction to MPSA to prepare a plan to put Cobre Panama on "care and maintenance". Currently, Cobre Panama's operations have not been impacted. First Quantum and MPSA have taken steps under domestic legal proceedings in Panama and international arbitration as a precautionary measure.

06:10 EST Rush Street selects Konami's SYNKROS system for Rivers Casino Portsmouth - Rush Street Gaming announced the selection of Konami Gaming's SYNKROS casino management system for Rivers Casino Portsmouth, a new world-class destination in Portsmouth, Va. Set to become the state's first permanent casino when it opens on January 15, 2023, Rivers Casino Portsmouth is the fifth location in Rush Street's portfolio to launch SYNKROS. Konami's award-winning casino management system will deliver seamless rewards, offers, communications, and more across Rivers Casino Portsmouth's 1,448 gaming machines, 57 table games, poker room, sportsbook, restaurant offering, retail environment, entertainment venues, and more.

06:02 EST First Quantum Minerals says talks resume on future of Cobre Panama - First Quantum Minerals issued the following update regarding the status of the Cobre Panama mine operated by its subsidiary Minera Panama. Formal discussions between First Quantum, MPSA and the Government of Panama resumed on December 26, 2022 regarding the long-term future of the Cobre Panama mine. The talks continued on December 27 and are ongoing. The Company remains committed to seeking a mutually beneficial agreement as soon as possible. Operations at Cobre Panama continue as normal at this time with no disruption to production. MPSA received formal notification from the National Directorate of Mineral Resources of the Ministry of Commerce and Industries on December 21, 2022 of a resolution requiring MPSA to submit a plan within 10 working days of such notification to suspend commercial operations at Cobre Panama and put the mine under "care and maintenance." MPSA is working through a number of steps to respond to the resolution, of which impact and timing are uncertain, and in order to address the complex practicalities of reducing operations of the size and scale of Cobre Panama. First Quantum continues to do everything possible to support the Cobre Panama workforce and protect its investment in the mine. As the Company has advised the Government of Panama, MPSA has initiated precautionary legal measures in the Panamanian courts and through arbitration under the existing Concession Contract. First Quantum has also notified the Government of its intent to initiate international arbitration under the Canada-Panama Free Trade Agreement.

05:51 EST AstraZeneca announces Calquence approved in Japan to treat CLL - AstraZeneca's Calquence, a selective Bruton's tyrosine kinase, or BTK, inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naive chronic lymphocytic leukaemia, or CLL. Calquence was previously approved in Japan for the treatment of adults with relapsed or refractory CLL.